The packaged-food aisle has become a graveyard for income stories, with GLP-1 drugs, private label, and tariffs squeezing every legacy brand. J.M. Smucker (NYSE:SJM | SJM Price Prediction) sits inside that storm with Folgers,…
Lucid (NASDAQ:LCID | LCID Price Prediction) at $5.19 faces a deteriorating risk/reward setup. The stock sits within striking distance of its 52-week low of $4.47, and the latest filings show a capital structure deteriorating…
Lockheed Martin (NYSE:LMT | LMT Price Prediction) is a stock worth owning for decades because its revenue is effectively underwritten by the U.S. government and a global alliance system that does not negotiate down…
Salesforce (NYSE:CRM | CRM Price Prediction) and Palantir (NASDAQ:PLTR) both delivered blowout quarters this spring, yet the market punished each stock. Salesforce posted $11.13B in revenue, up 13.3% YoY, leaning on Agentforce momentum. Palantir…
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) at $90.53 is a Buy. The healthcare giant has been swept up in a sector-wide rotation out of defensive names, even as its diabetes franchise compounds and…
NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) and Advanced Micro Devices (NASDAQ:AMD) both posted earnings confirming AI infrastructure dominates semis. NVIDIA reported a $75.246 billion Data Center quarter. AMD reported $5.775 billion. The scale gap…
SpaceX (NASDAQ:SPCX | SPCX Price Prediction) is the only ticker financial media wants to discuss this week after its blockbuster public debut at an implied trillion-dollar valuation. But here’s what you should actually be…
Eastman Chemical (NYSE: EMN | EMN Price Prediction) is a Kingsport, Tennessee specialty materials company whose molecular recycling (methanolysis) facility is reshaping its cash flow profile. Trading at $72.49 with a 4.56% yield, the…
Intel (NASDAQ:INTC | INTC Price Prediction) is the loudest ticker on Wall Street right now, riding a turnaround narrative powered by NVIDIA’s $5.0 billion equity stake, SoftBank’s $2.0 billion investment, and $8.9 billion in…
I keep hitting the buy button on Salesforce (NYSE:CRM | CRM Price Prediction), and I am not sorry about it. The stock sits at $152.76, down 42.03% year to date and 43.18% over the…
SpaceX (NASDAQ:SPCX | SPCX Price Prediction) and Tesla (NASDAQ:TSLA) sit on opposite sides of the same Elon Musk story. SpaceX debuted on June 12 and carries a $2.13 trillion market cap. Tesla closed Q1…
A 66-year-old with $1.3 million can’t afford a dividend cut. The hunt for yield often pushes retirees into mega-caps, but I think the real income value sits in mid-caps whose GAAP earnings are masked…
Republic Services (NYSE:RSG | RSG Price Prediction) is a stock built to be owned for decades, because it sits at the intersection of a non-discretionary service economy and a pricing model that compounds quietly…
I hit the buy button on AbbVie (NYSE:ABBV | ABBV Price Prediction) again last week, and I will hit it again the next time June’s macro noise hands me a discount. While short-term traders…
Air Products & Chemicals (NYSE:APD | APD Price Prediction) is a stock worth owning for decades because it sells an essential, contractually locked-in product into every corner of the global industrial economy and has…
S&P Global (NYSE:SPGI | SPGI Price Prediction) screens as a multi-decade compounder candidate because it operates a legally protected toll booth on global capital markets that almost every borrower, asset manager, and index fund…
At $381.61, Tesla (NASDAQ:TSLA | TSLA Price Prediction) looks vulnerable, with a credible path toward the $190 historical manufacturing support zone as tech multiples compress and global EV pricing grinds margins lower. The stock…
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) is a stock with characteristics suited to multi-decade ownership, because its four-segment healthcare engine, 54 consecutive years of dividend increases, and recession-resistant end markets give a retirement-focused…
At 60 with $800,000, the goal is yield without sleepless nights. Capital costs are climbing again, which squeezes any dividend payer that leans on debt markets. This analysis runs a margin-of-safety check on four…
Rivian (NASDAQ:RIVN | RIVN Price Prediction) at $14.89 is a Hold, with fresh capital best reserved unless a broader sector panic drags the equity toward $11.50. The stock has slid 24.45% year to date…
